DBS Solutions Inc

Laragen, located in Culver City, CA, is a leading provider of genetic sequencing and genotyping services. They offer a range of services including Sanger sequencing, MiSeq sequencing, mouse genotyping, and fragment analysis, among others. With their expertise in DNA analysis, Laragen is able to troubleshoot failed reactions and provide free repeats to ensure accurate results. They also offer proprietary chemistry for difficult templates and provide a quick turnaround time for sequencing and genotyping samples. At Laragen, they understand the importance of high-quality DNA templates for successful sequencing. They recommend using their recommended DNA prep kit and ensuring the correct primer concentration to avoid sequencing failures. With their state-of-the-art equipment and experienced team, Laragen is able to provide reliable and accurate sequencing results, allowing researchers and scientists to advance their genetic studies and discoveries.Generated from the website

MiraDx, located in Los Angeles, CA, is a pioneering company dedicated to advancing personalized cancer treatment through innovative genetic research. Co-founded by renowned experts Dr. Frank Slack and Dr. Joanne Weidhaas, the company focuses on tailoring cancer care plans based on individual patient responses and toxicity profiles to improve therapy outcomes. With groundbreaking tests like PROSTOX and PREVIOTOX, MiraDx empowers physicians to assess risks associated with radiation and immune checkpoint inhibitors, enhancing treatment strategies for cancer patients. Their commitment to utilizing novel biomarkers positions them at the forefront of personalized medicine, ultimately aiming to provide safer and more effective cancer care. Generated from the website

Indi Molecular, located in Culver City, CA, specializes in the development of synthetic small molecule targeted oncology therapeutics aimed at treating ovarian cancer and KRAS G12D expressing pancreatic cancers. Utilizing a breakthrough synthetic protein chemistry platform known as Protein Catalyzed Capture (PCC), the company creates small synthetic peptide replacements for traditional antibody-based therapies. The therapeutics produced by Indi Molecular exhibit specific targeting capabilities, demonstrating picomolar to low nanomolar binding affinities and fast synthesis processes. Their innovative approach ensures stable, water-soluble molecules that retain functional activity in vivo, potentially offering significant therapeutic effects against both intracellular and extracellular targets. Generated from the website